Amendments to the Specification:

(*Corrected version)* On page 6, delete the paragraph beginning on line 13 and replace it with the following paragraph:

> **Fig. 1** is a schematic diagram of the structure of a CAP of the invention and its constituents: (**A**) is an exemplary donor (FAM); (**B**) is an exemplary acceptor (TAMRA); and (**C**) is an exemplary stabilizing moiety (CHOL).

(*Marked-up version)* Below is the paragraph on page 6, beginning on line 13 which has been marked-up to show the amendments made.

> **Fig. 1** is a schematic diagram of the structure of a CAP of the invention and its constituents: ~~(**A**) is the assembled CAP;~~ (**B**A) is an exemplary donor (FAM); (~~C~~**B**) is an exemplary acceptor (TAMRA); and (~~D~~**C**) is an exemplary stabilizing moiety (CHOL).

(*Corrected version)* On page 54, delete the paragraph beginning on line 14 and replace it with the following paragraph:

A model CAP probe was synthesized using cholesterol as the hydrophobic ligand. In this simple model, cholesterol units were placed adjacent to both the donor and acceptor. The model sequence was B-Actin which is a well characterized probe used in the "Taqman" gene quantitation system (ABI-Perkin-Elmer). Both probes were 5'-FAM, 3'-TAMRA labeled as follows:

Taqman Probe

> 5'-FAM- d5'CGCAGGATGGCATGGGGGAGGGCAT-TAMRA-3'

(*Marked-up version)* Below is the paragraph on page 54, beginning on line 14 which has been marked-up to show the amendments made.

A model CAP probe was synthesized using cholesterol as the hydrophobic ligand. In this simple model, cholesterol units were placed adjacent to both the donor and acceptor ~~(Figure 1)~~. The model sequence was B-Actin which is a well characterized probe used in the "Taqman" gene quantitation system (ABI-Perkin-Elmer). Both probes were 5'-FAM, 3'-TAMRA labeled as follows:

Taqman Probe

5'-FAM- d5'CGCAGGATGGCATGGGGGAGGGCAT-TAMRA-3'